Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00446524
Status:
COMPLETED
Last Update Posted:
2017-03-28
First Post:
2007-03-09
Brief Title:
Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension Extension to Study CVAA489A1301
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 54-week Extension to the Multi-center Randomized Double-blind Parallel-group Placebo-controlled Factorial Study to Evaluate the Efficacy and Safety of VAA489 Valsartan and Amlodipine Combined and Alone in Essential Hypertensive Patients - Long Term Study of VAA489 in Patients With Essential Hypertension Extension From A1301 Study
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate long-term safety and tolerability of once daily administration of the combination of Valsartan and Amlodipine 805 mg for 52 weeks in patients with essential hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None